This content is machine translated European Lung Cancer Conference Mutation analysis is crucial for the choice of therapy Three interesting studies were presented at the European Lung Cancer Conference in Geneva. Two were dedicated to the group of NSCLC patients with an EGFR-activating mutation. Can erlotinib neoadjuvant achieve…
